Erasca, Inc. (NASDAQ:ERAS) announced plans for a sizeable equity raise on Monday, saying it intends to offer $500 million of common stock in an underwritten public offering. The company also disclosed that underwriters would be granted a 30-day option to purchase up to an additional $75 million of shares.
Following the filing of the proposed offering, Erasca's shares declined by 12% in after-hours trading. The company stated the proposed transaction is subject to market and other conditions and that the offering would be conducted on an underwritten basis.
According to the filing, Erasca intends to apply the net proceeds from the sale, together with its existing cash, cash equivalents, and marketable securities, toward advancing research and development of its product candidates and other development programs. The company also indicated the proceeds would be available for working capital and general corporate purposes.
Erasca identifies itself as a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients whose cancers are driven by abnormalities in the RAS/MAPK pathway.
The proposed offering will be led by a syndicate of joint book-running managers: J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI. The company’s filing explicitly notes there is no assurance regarding whether or when the offering may be completed, nor about the ultimate size or terms of any completed transaction.
Context and immediate market reaction
The announcement of a planned $500 million common stock offering, together with the potential for an additional $75 million via underwriter option, coincided with a marked drop in the company’s share price in after-hours trading. Erasca’s disclosure emphasizes the conditional nature of the offering - it is subject to market conditions and other contingencies - and the filing reiterates uncertainty around timing and final terms.
Financial intent
Erasca has stated that the funds are to be used primarily to support its drug development activities and related programs, supplemented by working capital and general corporate expenditures. The company will combine net proceeds from the offering with existing liquid resources to pursue these objectives.
Key facts at a glance
- Proposed offering: $500 million in common stock.
- Underwriters' option: 30-day option to buy up to an additional $75 million of shares.
- After-hours market reaction: shares fell 12% following the announcement.
The filing stresses the absence of certainty that the offering will be completed on the proposed terms or at all.